✦ LIBER ✦

Bupropion for Control of Hot Flashes in Breast Cancer Survivors: A Prospective, Double-Blind, Randomized, Crossover, Pilot Phase II Trial

✍ Scribed by Nuñez, Geila Ribeiro; Pinczowski, Hélio; Zanellato, Rebecca; Tateyama, Lívia; Schindler, Fernanda; Fonseca, Fernando; del Giglio, Auro

Book ID: 125421408
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 277 KB
Volume: 45
Category: Article
ISSN: 0885-3924
DOI: 10.1016/j.jpainsymman.2012.06.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled Crossover Trials of Venlafaxine for Hot Flashes After Breast Cancer

✍ Carpenter, J. S.; Storniolo, A. M.; Johns, S.; Monahan, P. O.; Azzouz, F.; Elam, 📂 Article 📅 2007 🏛 Alphamed Press 🌐 English ⚖ 260 KB

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen

✍ Gretchen G. Kimmick; James Lovato; Richard McQuellon; Emily Robinson; Hyman B. M 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB

6089 POSTER Goshajinkigan (TJ-107) for O

6089 POSTER Goshajinkigan (TJ-107) for Oxaliplatin-induced Sensory Neurotoxicity in Colorectal Cancer Patients – a Prospective, Randomized, Double-blinded, Placebo-controlled, Phase II Trial (GONE)

✍ Matsui, T.; Kono, T.; Hata, T.; Fukunaga, M.; Munemoto, Y.; Nagata, N.; Shimada, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

PD27-11 A PHASE II, RANDOMIZED, DOUBLE-B

PD27-11 A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF METHYLPHENIDATE FOR REDUCTION OF FATIGUE IN PROSTATE CANCER PATIENTS RECEIVING LHRH-AGONIST THERAPY

✍ Richard, Patrick O.; Fleshner, Neil E.; Bhatt, Jaimin R.; Hersey, Karen M.; Chah 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 43 KB

WSG ADAPT – adjuvant dynamic marker-adju

WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

✍ Hofmann, Daniel; Nitz, Ulrike; Gluz, Oleg; Kates, Ronald E; Schinkoethe, Timo; S 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 879 KB

Safety and efficacy of the novel antieme

Safety and efficacy of the novel antiemetic neurokinin-1 (NK-1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) – subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial

✍ J. Herrstedt; W. Arpornwirat; I. Albert; V.L. Hansen; R.R. Bandekar; J. Levin; S 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 74 KB